Fig. 7: Systemic delivery of IL-8 neutralizing antibody overrides NSCLC bone metastasis in nude mice. | Cell Death & Disease

Fig. 7: Systemic delivery of IL-8 neutralizing antibody overrides NSCLC bone metastasis in nude mice.

From: A novel microRNA-182/Interleukin-8 regulatory axis controls osteolytic bone metastasis of lung cancer

Fig. 7

A Schematic diagram illustrating the experimental design. The immunodeficient mice (5 for each group) were administered by IIA injection with miR-182-overexpressing A549 cells, followed by intravenous injection of IL-8 neutralizing antibody (0.1 mg/mouse) twice a week for 3 weeks. B–D IL-8 neutralizing antibody significantly inhibited bone metastasis formation in miR-182-overexpressing A549 cell-injected mice. At the treatment end (week 4), the bone-metastatic tumors were detected by BLI signals (B), bone damage was measured by micro-CT and quantified by BV/TV (C), and tumor-induced osteoclastogenesis was analyzed by TRAP staining, with TRAP-positive osteoclasts indicated by arrowheads (D). E Co-immunostaining of p-STAT3 (red) and the osteoclast marker CTSK (green) in distal femurs from two groups at the treatment end (week 4) (left). Quantification of p-STAT3+ osteoclasts in metastatic lesions (right). Scale bars, 50 μm. The average values ± SEM of three separate experiments are plotted. **P < 0.01; ***P < 0.001.

Back to article page